Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...

AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.

(UroToday.com) The 2026 SESAUA annual meeting featured the Gee-Dineen lecture series and a presentation by Dr. Andrew Harris discussing the state of the Urology workforce. Dr. Harris started his ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...

Hashim Hashim joins Diane Newman for a conversation on the definitions of lower urinary tract dysfunction and the role and timing of urodynamics in the diagnosis of the specific condition. They also ...

MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses - Beyond the Abstract ...

The Kurt extraperitoneal ligamentopexy: A new surgical method with uterine preservation for pelvic organ prolapse, "Beyond the Abstract," by Sefa Kurt and Mehmet Tunc Canda ...

ASCO GU 2023 Press Releases Clinical Data Presented at ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC Cabometyx® in Combination with ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a urology trials in bladder and prostate cancer session and a presentation by Dr. Christian Engesser discussing ...

(UroToday.com) The 2023 European Society of Medical Oncology (ESMO) Annual Congress held in Madrid, Spain between October 20 th and 24 th, 2023 was host to a non-prostate, genitourinary tumors mini ...

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Fred Saad discussing the efficacy and safety of darolutamide plus ADT in patients ...